August 13th 2021
By Tony Hagen
Passage of HR 3 is shaping up as a centerpiece of President Biden's effort to bring pharmaceutical prices under control. If drug companies won't negotiate prices, international reference pricing would kick in.
August 12th 2021
When it comes to their willingness to use biosimilars, providers and managed care pharmacists prefer greater transparency on formulary placement and costs, according to a focus group study based on health care surveys.
August 11th 2021
Semglee (insulin glargine) will be the first test of the FDA's interchangeability concept for biosimilars, but Viatris aims to grow its biosimilar revenues with multiple products.
August 2nd 2021
By Deana Ferreri, PhD
The average net price of all insulin glargine products decreased between 2015 and 2020 following the steady price increase seen for Lantus from 2010 to 2014.
July 29th 2021
By Jeff Baldetti, MBA
The approval of Biocon Biologics and Viatris' insulin glargine product as an interchangeable biosimilar will be a test of whether such designations can make a difference in patient access, Jeff Baldetti, MBA, of Cardinal Health explains.
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin.
July 23rd 2021
Biocon reports on its revenues from biosimilars and the FDA status of its insulin glargine product.
July 15th 2021
Panelists at the American Conference Institute's 2021 meeting took on the complexities of biosimilar adoption in a wide-ranging discussion.
July 10th 2021
Biosimilars are launching at significant discounts to reference products and capturing increasing market share, according to an Amgen report.
July 8th 2021
In a white paper, the International Generic and Biosimilar Medicines Association (IGBA) describes industry dynamics that it says affect market sustainability and patient access.
